Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy
Dina, E., Nasser, M., Sarah, E., Mahmoud, A., Islam, M., Waleed, E., Muhammad, D. (2020). Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy. EKB Journal Management System, 4.2(2), 69-73. doi: 10.21608/mjvh.2020.80655
Elhammady Dina; Mousa Nasser; Eissa Sarah; Awad Mahmoud; Mohamed Islam; Eldars Waleed; Diasty Muhammad. "Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy". EKB Journal Management System, 4.2, 2, 2020, 69-73. doi: 10.21608/mjvh.2020.80655
Dina, E., Nasser, M., Sarah, E., Mahmoud, A., Islam, M., Waleed, E., Muhammad, D. (2020). 'Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy', EKB Journal Management System, 4.2(2), pp. 69-73. doi: 10.21608/mjvh.2020.80655
Dina, E., Nasser, M., Sarah, E., Mahmoud, A., Islam, M., Waleed, E., Muhammad, D. Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy. EKB Journal Management System, 2020; 4.2(2): 69-73. doi: 10.21608/mjvh.2020.80655

Pretreatment serum alpha fetoprotein and its relation to sustained virologic response in patients with chronic HCV infection treated with direct-acting antiviral therapy

Medical Journal of Viral Hepatitis
Article 4, Volume 4.2, Issue 2, March 2020, Page 69-73  XML PDF (209.01 K)
Document Type: Original article
DOI: 10.21608/mjvh.2020.80655
View on SCiNiTO View on SCiNiTO
Authors
Elhammady Dina1; Mousa Nasser2; Eissa Sarah1; Awad Mahmoud3; Mohamed Islam3; Eldars Waleed4; Diasty Muhammad1
1Tropical Medicine dept., Faculty of Medicine, Mansoura Univ., Mansoura, Egypt
2Tropical Medicine dept, Faculty of Medicine, Mansoura Univ., Egypt.
3Internal Medicine dept., Faculty of Medicine, Mansoura Univ., Mansoura, Egypt
4Medical Microbiology and Immunology dept., Faculty of Medicine, Mansoura Univ, Mansoura, Egypt
Abstract
Background and study aim. The introduction
of directacting antiviral agents (DAAs) has
increased sustained virologic response (SVR) rates in
patients with chronic hepatitis C infection (CHC). The
aim of this study is to evaluate the efficacy of DAAs
in treatment of Egyptian patients with CHC, and to
determine the parameters associated with non-response
to DAAs Patients and methods. This study included
200 treatment-naïve chronic hepatitis C patients who
were divided into two groups and treated according
to the Egyptian National Treatment Program for
Hepatitis C Virus. Group 1 consisted of 100 easy-totreat
patients who were administered sofosbuvir 400
mg daily/daclatasvir 60 mg daily for 3 months, while
group 2 included 100 difficult-to-treat patients treated
by Sofosbuvir 400 mg/ daclatasvir 60 mg /ribavirin
daily for 3 months Results. The overall patient sustained
virologic response (SVR) in the present study
was 93.5% (187/200). SVR in group 1 was 100%, while
group 2 showed SVR of 87% (87/100). Comparison
between patients with and without SVR revealed no
statistically significant differences regarding age and
sex distribution, serum albumin, bilirubin, transaminases
level, INR and platelets count. However,
patients who were non-responders had signi-ficantly
higher pre-treatment alpha fetoprotein (AFP) levels
than responders Conclusions. Treatment of CHC
pati-ents with DAAs is associated with higher
sustained virologic response, particularly in easy-totreat
patients. AFP level may aid in prediction of
non-responders to DAAs
Keywords
Hepatitis C virus; Direct-acting antiviral agents; Sustained virologic response; Alpha fetoprotein
Statistics
Article View: 222
PDF Download: 469